Login / Signup

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.

Renata FerrarottoDiana BellMaria L RubinKatherine A HutchesonJason M JohnsonRyan P GoepfertJack PhanYasir Y ElaminDanice K TormanCarla L WarnekeAmy C HesselAdam S GardenJeffrey N MyersFaye M JohnsonJ Jack LeeAndrew G SikoraMaura L GillisonBonnie S GlissonNeil D Gross
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Durvalumab + tremelimumab did not increase CD8+TIL density more than durvalumab alone did. The observed safety and activity support further investigation of neoadjuvant checkpoint inhibitor for OPC.
Keyphrases
  • rectal cancer
  • locally advanced
  • lymph node
  • papillary thyroid
  • dna damage
  • clinical trial
  • nk cells
  • study protocol
  • cell cycle
  • phase iii
  • squamous cell
  • squamous cell carcinoma
  • oxidative stress
  • cell proliferation